No black box warning on record for Itovebi

As of the latest FDA labeling reviewed, Itovebi (INAVOLISIB) does not carry a black box warning. Standard warnings and precautions still apply — see the full Itovebi medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hyperglycemia : ITOVEBI can cause severe or fatal hyperglycemia including ketoacidosis. Before initiating treatment with ITOVEBI, test fasting plasma glucose (FPG), HbA1c, and optimize blood glucose. Initiate or optimize anti-hyperglycemic medications as clinically indicated. Interrupt, reduce dose, or discontinue ITOVEBI if severe hyperglycemia occurs. ( 2.4 , 5.1 ) Sto

No black box warning on record for Itovebi

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Hyperglycemia : ITOVEBI can cause severe or fatal hyperglycemia including ketoacidosis. Before initiating treatment with ITOVEBI, test fasting plasma glucose (FPG), HbA1c, and optimize blood glucose. Initiate or optimize anti-hyperglycemic medications as clinically indicated. Interrupt, reduce dose, or discontinue ITOVEBI if severe hyperglycemia occurs. ( 2.4 , 5.1 ) Sto

Itovebi Black Box Warning

No black box warning on record for Itovebi

Other warnings & precautions

Itovebi Black Box Warning

No black box warning on record for Itovebi

Other warnings & precautions